Video

Treatment Sequencing in LBCL: Clinical Trial and Real-World Data

Author(s):

Manali Kamdar, MD,Matthew A. Lunning, DO, FACP

Experts discuss the role of clinical and real-world data in informing treatment sequencing in patients with large B-cell lymphoma (LBCL) in the academic and community setting,

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss ongoing research to watch in prostate cancer.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss other key prostate cancer data presented at ASCO GU 2025.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss data from a real-world analysis for AR inhibitors in nmCRPC.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss a subgroup analysis from the ARANOTE trial in prostate cancer.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss an age-based subgroup analysis from the ARASENS trial in prostate cancer.
Julie M. Vose, MD, MBA
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss the evolution of treatment for metastatic hormone-sensitive prostate cancer.
Marco Davila, MD, PhD, the senior vice president and associate director for Translational Research in the Department of Medicine, as well as the Rustum Family Endowed Chair in Translational Research at Roswell Park Comprehensive Cancer Center
Pooja Phull, MD
Sairah Ahmed, M.D
Related Content
Renier Brentjens, MD, PhD, chair of the Department of Medicine, the Katherine Anne Gioia Endowed Chair in Cancer Medicine, deputy director, and a professor of oncology at Roswell Park Comprehensive Cancer Center
March 12th 2025

Investigators Are Making Headway Bringing CAR T-Cell Therapy to Solid Tumors

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

Cema-Cel in R/R LBCL | Image Credit: © LASZLO – stock.adobe.com
March 11th 2025

Cema-Cel Induces CRs and Has Manageable Safety Profile in CD19 CAR T-Cell Therapy–Naive R/R LBCL

Matthew Lunning, DO, FACP
October 30th 2023

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

Perioperative pembrolizumab sBLA gets priority review in HNSCC, nivolumab/ipilimumab sBLA in MSI-H/dMMR CRC is under review, and more from OncLive this week.
March 1st 2025

The OncFive: Top Oncology Articles for the Week of 2/23

Here is your snapshot for all therapeutic options that were approved by the FDA in February 2025 spanning tumor types.
March 1st 2025

OncLive’s FDA Approval Report: The Regulatory Rundown for February 2025